LIMN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Liminatus Pharma Inc (LIMN) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows no significant trading trends, lacks positive news or catalysts, and has weak financial performance. Additionally, technical indicators suggest a bearish trend, and no proprietary trading signals indicate a strong buy opportunity. Holding off on investing in this stock is advisable until more favorable conditions arise.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 24.741, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its key support level of 0.202, with resistance levels at 0.231 and 0.261. Overall, the technical indicators suggest a bearish trend.
NULL identified. No recent news or significant trading trends from hedge funds or insiders.
Bearish moving averages, weak financial performance, and lack of significant trading trends or news.
In Q3 2025, the company reported no revenue growth (0% YoY). Net income improved to -1,823,351 (up 202.98% YoY), and EPS improved to -0.07 (up 250% YoY). However, the company remains unprofitable, with no gross margin or revenue growth.
No analyst rating or price target data available.
